Evidence map›Paper›PMID 25966442›Full record

ArticleAtherosclerosis2015

Glutaredoxin 2a overexpression in macrophages promotes mitochondrial dysfunction but has little or no effect on atherogenesis in LDL-receptor null mice.

D A Zamora, K P Downs, S L Ullevig, S Tavakoli, H S Kim, M Qiao, D R Greaves, R Asmis

Abstract read
In one paragraph

Article in Atherosclerosis, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Redox RegulationAntioxidants & redox signaling · 2020
    Review
  7. mTOR drives cerebral blood flow and memory deficits in LDLRJournal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

D A ZamoraDepartment of Biology, Trinity University, San Antonio, USA.
K P DownsDepartment of Clinical Laboratory Sciences, University of Texas Health Science Center at San Antonio, USA.
S L UllevigDepartment of Kinesiology, Health, and Nutrition, University of Texas at San Antonio, San Antonio, USA.
S TavakoliDepartment of Radiology, University of Texas Health Science Center at San Antonio, San Antonio, USA.
H S KimDepartment of Clinical Laboratory Sciences, University of Texas Health Science Center at San Antonio, USA.
M QiaoDepartment of Clinical Laboratory Sciences, University of Texas Health Science Center at San Antonio, USA.
D R GreavesSir William Dunn School of Pathology, University of Oxford, Oxford, United Kingdom.
R AsmisDepartment of Clinical Laboratory Sciences, University of Texas Health Science Center at San Antonio, USA; Department of Radiology, University of Texas Health Science Center at San Antonio, San Antonio, USA; Department of Biochemistry, University of Texas Health Science Center at San Antonio, USA. Electronic address: asmis@uthscsa.edu.
The University of Texas Health Science Center at San Antonio · USThe University of Texas at San Antonio · USTrinity University · USUniversity of Oxford · GB

Funding

PATHOBIOLOGY OF OCCLUSIVE VASCULAR DISEASET32HL007446 · NHLBI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Jean Chrisostome Bopassa · 1985 to 2026
$8.9M
Role of Glutathione Reductase and Macrophage OncosisR01HL070963 · NHLBI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI ASMIS, RETO H.R. · 2002 to 2010
$2.8M
Nox4 and the Redox-Regulation of MKPs in Monocyte Recruitment and AtherosclerosisR01HL115858 · NHLBI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI ASMIS, RETO H.R. · 2012 to 2015
$1.6M
British Heart Foundation RG/10/15/28578NHLBI NIH HHS HL115858NHLBI NIH HHS HL70963NHLBI NIH HHS R01 HL070963NHLBI NIH HHS R01 HL115858NHLBI NIH HHS T32 HL007446
6 · The paper itself

Abstract

aimsReactive oxygen species (ROS)-mediated formation of mixed disulfides between critical cysteine residues in proteins and glutathione, a process referred to as protein S-glutathionylation, can lead to loss of enzymatic activity and protein degradation. Since mitochondria are a major source of ROS and a number of their proteins are susceptible to protein-S-glutathionylation, we examined if overexpression of mitochondrial thioltranferase glutaredoxin 2a (Grx2a) in macrophages of dyslipidemic atherosclerosis-prone mice would prevent mitochondrial dysfunction and protect against atherosclerotic lesion formation. METHODS AND

resultsWe generated transgenic Grx2aMac(LDLR-/-) mice, which overexpress Grx2a as an EGFP fusion protein under the control of the macrophage-specific CD68 promoter. Transgenic mice and wild type siblings were fed a high fat diet for 14 weeks at which time we assessed mitochondrial bioenergetic function in peritoneal macrophages and atherosclerotic lesion formation. Flow cytometry and Western blot analysis demonstrated transgene expression in blood monocytes and peritoneal macrophages isolated from Grx2aMac(LDLR-/-) mice, and fluorescence confocal microscopy studies confirmed that Grx2a expression was restricted to the mitochondria of monocytic cells. Live-cell bioenergetic measurements revealed impaired mitochondrial ATP turnover in macrophages isolated from Grx2aMac(LDLR-/-) mice compared to macrophages isolated from non-transgenic mice. However, despite impaired mitochondrial function in macrophages of Grx2aMac(LDLR-/-) mice, we observed no significant difference in the severity of atherosclerosis between wildtype and Grx2aMac(LDLR-/-) mice.

conclusionOur findings suggest that increasing Grx2a activity in macrophage mitochondria disrupts mitochondrial respiration and ATP production, but without affecting the proatherogenic potential of macrophages. Our data suggest that macrophages are resistant against moderate mitochondrial dysfunction and rely on alternative pathways for ATP synthesis to support the energetic requirements.

Indexed as

Adenosine TriphosphateAnimalsAortaAortic DiseasesApoptosisAtherosclerosisCells, CulturedDisease Models, AnimalEnergy MetabolismGlutaredoxinsMacrophages, PeritonealMice, Inbred C57BLMice, KnockoutMitochondriaPlaque, AtheroscleroticReceptors, LDLAdenosine TriphosphateGlrx2 protein, mouseGlutaredoxinsReceptors, LDLAtherosclerosisGlutaredoxin 2MacrophageMitochondriaReactive oxygen speciesThiols

Identifiers

PMID25966442
PMCPMC4466159
OpenAlexW1979848111

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.